Latest News
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
4 July 2025 - Global biopharmaceutical company AstraZeneca (LSE/STO/NASDAQ:AZN) announced on Friday that it has received European Union approval for Imfinzi (durvalumab) as the first and only perioperative immunotherapy for adult patients with resect...
INOVIO prices USD25m public offering
4 July 2025 - INOVIO Pharmaceuticals Inc (Nasdaq:INO), a US-based biotechnology company involved in developing and commercialising DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, announced on...
BioLab Holdings' amnion grafts enter multicentre clinical trial
4 July 2025 - BioLab Holdings Inc, a US-based medical manufacturer specialising in wound healing and regenerative therapies, announce on Thursday the launch of a multicentre hybrid platform trial evaluating the clinical effectiveness of its amnion-ba...
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
4 July 2025 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Thursday the successful enrolment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4...
Biocon Biologics' Denosumab biosimilars receive European Commission approval
4 July 2025 - India-based biosimilars company Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, announced on Thursday that the European Commission has granted marketing authorisation in the European Union for its Vevzuo and Evfraxy biosimilars ...